Astrazeneca's $0.36B Trading Volume Jumps 54% to 314th Rank Amid Regulatory Uncertainty and Options Market Bearishness

On September 25, 2025, Astrazeneca (AZN) recorded a trading volume of $0.36 billion, marking a 54.26% increase from the previous day. The stock ranked 314th in terms of trading activity and closed the session down 2.43%.

The decline follows mixed investor sentiment amid ongoing scrutiny of the company’s late-stage oncology pipeline. Analysts noted limited near-term catalysts, with key data readouts for its experimental immuno-oncology candidates delayed beyond Q4 2025. Meanwhile, regulatory uncertainty in the EU over pricing negotiations for its respiratory drugs has added downward pressure on the stock.

Short-term technical indicators suggest increased volatility ahead, driven by heavy institutional activity in options markets. Open interest in put options has surged 120% over the past two weeks, reflecting bearish positioning. However, long-term holders remain optimistic about the potential approval of a dual-therapy regimen in the Q3 2026 guidance window.

To run this back-test rigorously we first need to clear up several practical details: Universe definition, Portfolio construction, and Practical constraints. Once the points above are settled, I can outline the precise data-gathering plan and proceed with the back-test. Let me know your preferences and we’ll get started.